GigaGen Signs $135 Million US Contract for Manufacturing and Testing

Grifols’ biotechnology subsidiary, GigaGen, has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) of the United States for up to $135.2 million over a period of six years for the manufacture of products in two programs and Phase I trials.

According to a statement from the company on Thursday, it must develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNT) and a “second biological threat of interest to the agency to be determined at a later date.”

GigaGen CEO Carter Keller said the company “aims to change the way infectious diseases are treated” and welcomed the collaboration with the U.S. government.

Grifols expected revenues of 930 million euros in July from the sale of Yimmugo in the United States

Biotest, also part of the Grifols group, forecast in July revenues of approximately one billion dollars (930.4 million euros) from sales in the United States of its intravenous immunoglobulin (Ig) Yimmugo over the next seven years, the blood derivatives company announced in a statement on Monday.

This forecast is part of the recent approval by the US Food and Drug Administration (FDA) of this drug to treat primary immunodeficiencies. The Catalan company recalls that Yimmugo is the first Biotest drug produced at the Next Level plant in Dreieich (Germany) to be marketed in the United States .

In this context, this plant has recently been certified by the FDA and already has approval for production and marketing in Europe, where Yimmugo has been sold since the end of 2022.

Yimmugo will be launched in the United States during the first quarter of 2025 and will be distributed by Kedrion thanks to a seven-year agreement with Biotest, which is part of the Grifols Group’s broad distribution strategy to ensure extensive reach and availability of its Ig therapies. He also recalled that the Grifols Group and Kedrion have a long-standing collaborative relationship.

__

(Featured image by Hal Gatewood via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us